Unique ID issued by UMIN | C000000262 |
---|---|
Receipt number | R000000312 |
Scientific Title | A phase I/II study of transjugular-transhepatic peritoneo-venous shunting for malignant ascites (JIVROSG-0201) |
Date of disclosure of the study information | 2007/09/01 |
Last modified on | 2005/10/10 14:55:50 |
A phase I/II study of transjugular-transhepatic peritoneo-venous shunting for malignant ascites (JIVROSG-0201)
Transjugular-transhepatic peritoneo-venous shunting for malignant ascites(JIVROSG-0201)
A phase I/II study of transjugular-transhepatic peritoneo-venous shunting for malignant ascites (JIVROSG-0201)
Transjugular-transhepatic peritoneo-venous shunting for malignant ascites(JIVROSG-0201)
Japan |
Cancer-related refractory ascites
Gastrointestinal surgery |
Malignancy
NO
To evaluate the safety and efficacy of transjugular-transhepatic peritoneo-venous shunting in patients with cancer-related refractory ascites.
Safety,Efficacy
Explanatory
Phase I,II
Adverse events
Improvement of symptom, decrease of ascites and body weight, elimination of
Interventional
Single arm
Non-randomized
Open -no one is blinded
Uncontrolled
1
Treatment
Maneuver |
Under local anesthesia, a route from jugular vein reaching to the abdominal cavity through the superior vena cava, hepatic vein and liver parenchymal tissue is made, and then, a transjugular-transhepatic peritoneo-venous shunting catheter is placed.
Not applicable |
Not applicable |
Male and Female
1) Symptomatic refractory ascites adversely influencing on QOL.
2) Patent superior vena cava and hepatic vein confirmed by CT.
3) Serous ascites.
4) Adequate cardiac, hepatic, renal, respiratory, and bone marrow functions.
5) Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 3.
6) Expected survival over 4 weeks.
7) Written informed consent.
1) Controllable ascites by standard anti-cancer therapies.
2) Intracavitary administration of anti-cancer agent is scheduled.
3) Controllable ascites by vascular interventions.
4) No symptom due to ascites.
5) Ascites due to malignatnt mesothelioma, mucin-producting tumor, pseudomyxoma.
6) Bloody, chylous or cloudy ascites.
7) Tumor or dilated intestine along the planned route for catheterization.
8) Active infection.
9) Untreated esophageal varices with red-color sign.
10) Active bleeding from upper digestive tract.
11) Post hepatic lobectomy.
12) Cardiac pacemaker.
13) Pregnancy.
33
1st name | |
Middle name | |
Last name | Yasuaki Arai |
National Cancer Center Hospital
Division of Diagnostic Radiology
5-1-1,Tsukiji,Chuo-ku,Tokyo,104-0045,Japan
1st name | |
Middle name | |
Last name | Yasuaki Arai |
JIVROSG, Coordinating Office
Division of Diagnostic Radiology, National Cancer Center Hospital
5-1-1,Tsukiji,Chuo-ku,Tokyo,104-0045,Japan
Japan Interventional Radiology in Oncology Study Group (JIVROSG)
Ministry of Health, Labour and Welfare
Japan
NO
2007 | Year | 09 | Month | 01 | Day |
Unpublished
2002 | Year | 11 | Month | 30 | Day |
2003 | Year | 02 | Month | 01 | Day |
2007 | Year | 06 | Month | 01 | Day |
2007 | Year | 07 | Month | 01 | Day |
2007 | Year | 07 | Month | 01 | Day |
2007 | Year | 09 | Month | 01 | Day |
2005 | Year | 10 | Month | 10 | Day |
2005 | Year | 10 | Month | 10 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000000312